Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + trastuzumab + aromatase inhibitor
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy regimen consisting of pyrotinib, trastuzumab, and an aromatase inhibitor (AI). Pyrotinib is an oral, irreversible pan-HER tyrosine kinase inhibitor (TKI) that targets EGFR (HER1), HER2, and HER4. Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). Aromatase inhibitors (such as letrozole, anastrozole, or exemestane) are endocrine therapies that block the enzyme aromatase, thereby reducing estrogen production. This triplet combination is being investigated by the Tianjin Medical University Cancer Institute and Hospital as a neoadjuvant (preoperative) treatment for patients with stage II-IIIA hormone receptor-positive (HR+) and HER2-positive breast cancer, aiming to achieve synergistic anti-tumor effects through simultaneous dual HER2 blockade and estrogen deprivation.
- Other names
- pyrotinib + trastuzumab + AIpyrrolitinib + trastuzumab + AI
02
Targets
AR (Adrenergic receptors)EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on pyrotinib + trastuzumab + aromatase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + trastuzumab + aromatase inhibitor.